Carlsmed Analyst Price Targets - Benzinga

Carlsmed Inc

CARLNASDAQ

Trade with Public

Trade with Public

$15.77

0.463%

Últ. Act.: Oct 30, 8:08 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

© 2026 Benzinga | All Rights Reserved

Carlsmed Analyst Price Targets - Benzinga

Carlsmed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Carlsmed (CARL).

Price Target Range — 5 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$19Upside to Avg. PT+20.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	BTIG	Ryan Zimmerman	PT Raise	Buy	$23→$24
Sep 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$23
Aug 6, 2026	Truist Securities	Richard Newitter	PT Raise	Buy	$18→$20
Jul 1, 2026	Needham	David Saxon	Initiate	Buy	$17
May 6, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$23
Apr 15, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$20→$18
Apr 9, 2026	Goldman Sachs	David Roman	PT Cut	Buy	$19→$17
Dec 15, 2025	BTIG	Ryan Zimmerman	Maintained	Buy	$24
Nov 7, 2025	Truist Securities	Richard Newitter	PT Raise	Buy	$18→$20
Nov 7, 2025	BTIG	Ryan Zimmerman	PT Raise	Buy	$21→$24
Aug 18, 2025	Truist Securities	Richard Newitter	Initiate	Buy	$18
Aug 18, 2025	Goldman Sachs	David Roman	Initiate	Buy	$19
Aug 18, 2025	Piper Sandler	Matt O'Brien	Initiate	Overweight	$18

Analyst Ratings News

PRO
BTIG Maintains Buy on Carlsmed, Raises Price Target to $24

BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $23 to $24.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target

BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
Needham Initiates Coverage On Carlsmed with Buy Rating, Announces Price Target of $17

Needham analyst David Saxon initiates coverage on Carlsmed (NASDAQ:CARL) with a Buy rating and announces Price Target of $17.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Carlsmed, Lowers Price Target to $18

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and lowers the price target from $20 to $18.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Carlsmed, Lowers Price Target to $17

Goldman Sachs analyst David Roman maintains Carlsmed (NASDAQ:CARL) with a Buy and lowers the price target from $19 to $17.

Benzinga Newsdesk